Dr. Ray D. Page, DO

Dr. Page practices at The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave) in Fort Worth, Texas.

Dr. Page's NPI, 1669422143, was assigned on May 12, 2006. Dr. Page graduated from Texas College of Osteopathic Medicine in 1991. Dr. Page holds Texas license J2247.

Dr. Page's primary practice is The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave), at 800 W Magnolia Ave, Fort Worth, TX 76104 in Tarrant County. The practice phone is (817) 759-7000.

Dr. Page's primary practice is The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave) in Fort Worth, Texas. Dr. Page is also affiliated with Texas Health Fort Worth. The medical group on file is The Center for Cancer and Blood Disorders. Dmand AI also links Dr. Page to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Page practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Page's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Page is board certified in oncology by the AOA Board of Internal Medicine. Dr. Page is licensed in Texas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Page treats.

CMS data shows 86,857 Medicare services from Dr. Page across 40 procedure codes in 2024, for 433 Medicare patients. Medicare paid $581,155 for them. Every service was in an office.

CMS counts 433 Medicare patients who saw Dr. Page in 2024. The largest group is 75 to 84, with 178 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Page's median patient age at 72, with 56% women.

In 2024, Dr. Page wrote 1,167 Medicare Part D claims for 196 patients. 72% of them were for generic drugs. CMS names the drug for 921 of them, across 31 drugs with 11 or more claims each, at $3,805,998 in total drug cost. In 2023, CMS named 751 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Page for performance year 2024, reported individually. Dr. Page accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Page as offering telehealth.

Dmand AI links 90 papers to Dr. Page, published from 2005 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Medical Oncology, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Dr. Page has published most often in J Oncol Pract. Dr. Page's most frequent co-authors are Blase N. Polite, Linda Diana Bosserman, FACP, MD and Mark A. Socinski, MD.

Dmand AI links Dr. Page to 16 clinical trials, 6 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Page that name 1 trial.

CMS Open Payments shows 1,031 general payments to Dr. Page from 90 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Daiichi Sankyo Inc. paid the most, $5,385. It also lists 10 research payments totaling $127,711 from 2016 to 2017, naming 1 clinical trial.

Dmand AI lists 19 awards for Dr. Page, most recently NCQA PPC in 2014.

Dr. Page graduated from Texas College of Osteopathic Medicine in 1991. Dr. Page is a member of AOA and ASCO.

Dr. Page is in network with 18 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.